SMARCA5 and acute myeloid leukemia: To characterize the effect of SMARCA5 deletion in the AML-S5KO subclones, we monitored their growth in culture by the WST-1 assay correlating the number of metabolically active cells in the 72-hr culture within a 96-well plate.